Alzheimer's drug development pipeline, as of Q2 2026

Scope

This snapshot summarizes the mechanism-by-mechanism structure of the late-stage Alzheimer's pipeline as of Q2 2026. The focus is programs in or near phase 3 registration trials, with notes on meaningful phase 2 activity where it is likely to read out within the next twelve to eighteen months. For the synthesis view of what the pipeline adds up to, see our Insight on the post-amyloid pipeline as a portfolio bet.

Anti-amyloid antibodies - mature

Two FDA-approved products (lecanemab, donanemab) define the current in-market anti-amyloid class. The meaningful near-term development in this category is not a new molecule - it is subcutaneous reformulation, now progressing through regulatory review. Subcutaneous availability would materially change the delivery profile and the operational bottlenecks discussed in our Insight on the rate-limited rollout. Discussed in our coverage of subcutaneous anti-amyloid formulations.

Combination and next-generation anti-amyloid programs are active in earlier development, but none is a late-stage candidate at this snapshot date.

Anti-tau approaches

Tau pathology correlates more closely with cognitive decline than amyloid burden, and the tau programs are the most mechanistically proximate challenger to anti-amyloid therapy.

Several modalities are active:

• Anti-tau monoclonal antibodies - multiple programs in phase 2 and phase 3 development, typically enrolling patients selected by tau PET or plasma tau readouts. Readouts across the next 12–24 months will be the field-shaping reads to watch.
• Antisense oligonucleotides (ASOs) against tau - mid-stage development, CSF delivery.
• Aggregation inhibitors and post-translational-modification approaches - varied stages, generally earlier than the antibody programs.

A clinically meaningful tau readout would extend the disease-modification toolkit and would intensify - not resolve - the CDR-SB meaningfulness debate. It would also immediately expose the tau PET reimbursement question, which gates the actual eligible population. See our coverage of tau-targeting programs.

GLP-1 receptor agonists

GLP-1 receptor agonists - best known for type 2 diabetes and weight management - are the most consequential cross-category entrant in Alzheimer's, with late-stage programs evaluating cognitive and functional outcomes in early Alzheimer's populations.

• Semaglutide - phase 3 Alzheimer's readouts are imminent.
• Other GLP-1 / GIP agonists - phase 2 signals under active interpretation.

The mechanism of action in Alzheimer's remains debated - metabolic, inflammatory, direct neuronal effects are all plausible contributors - but the readouts will be informative either way. See our coverage of GLP-1 receptor agonists in Alzheimer's.

Neuroinflammation

Microglia-modulating approaches and broader anti-inflammatory strategies are advancing, generally at earlier stages than tau or anti-amyloid programs.

• TREM2 agonists - mid-stage clinical development.
• CSF1R modulators - earlier stages.
• Targeted anti-inflammatory strategies - varied stages, several phase 2 readouts in the next 12 months.

Biomarker validation - particularly the relationship between imaging or CSF inflammation markers and clinical endpoints - remains a central open question for this category.

Synaptic and neuronal resilience

Programs targeting the maintenance of synaptic function in the face of accumulating pathology are mechanistically diverse, largely in early- to mid-stage development. The interest here is less about a single program and more about whether any of these approaches produces a readout that validates the broader resilience thesis - which would change how the rest of the pipeline is combined and sequenced.

Genetic and protein-clearance approaches

The most upstream biological category. Late-stage candidates are sparse; the active programs are earlier.

• APOE-targeting approaches - including antibody and gene-directed strategies. Early clinical stages for the most advanced programs.
• Lysosomal-pathway modulators - early- to mid-stage development.
• Other protein-clearance strategies - varied, mostly earlier.

The thesis is that addressing upstream biology may complement amyloid clearance rather than replace it, and the operational implication is that any readout would likely reshape the combination-therapy landscape rather than the monotherapy landscape.

Endpoints

Late-stage Alzheimer's trials continue to use CDR-SB and iADRS as primary cognitive/functional endpoints, with amyloid and tau PET for target engagement. For the reference set of endpoints and how to read a readout, see our snapshot of clinical trial endpoints.

Regulatory and reimbursement context

Post-aducanumab, the FDA bar for biomarker-only approvals has meaningfully risen - see our Signal on accelerated approval scrutiny. For any new mechanism, confirmatory clinical endpoints are now generally expected as part of a durable approval path, and the downstream payer picture - discussed in our payer-coverage snapshot - will shape the economics of anything that reads out positive.

What we are watching

The most consequential near-term readouts are the tau program registration studies, the phase 3 GLP-1 results, and the mid-stage neuroinflammation signals. None of them individually will change the field in a single quarter; collectively they will determine how the next era of treatment is shaped. As the mix of positive, negative, and ambiguous readouts accumulates, the strategic question becomes less "which mechanism wins" and more "which combinations and sequences are worth building."

This snapshot is updated when material changes occur in late-stage pipeline status.